Yield10 Bioscience Inc (YTEN) Given Consensus Rating of “Strong Buy” by Analysts

Shares of Yield10 Bioscience Inc (NASDAQ:YTEN) have received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus price objective of $7.50 for the company, according to Zacks. Zacks has also assigned Yield10 Bioscience an industry rank of 109 out of 255 based on the ratings given to related companies.

Separately, Maxim Group reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Yield10 Bioscience in a research note on Friday, September 21st.

Shares of NASDAQ:YTEN traded down $0.02 during trading on Friday, hitting $1.40. The company had a trading volume of 163,695 shares, compared to its average volume of 45,974. The firm has a market capitalization of $14.42 million, a price-to-earnings ratio of -0.43 and a beta of 3.16. Yield10 Bioscience has a one year low of $1.12 and a one year high of $8.67. The company has a debt-to-equity ratio of 0.10, a current ratio of 6.82 and a quick ratio of 6.82.

Yield10 Bioscience (NASDAQ:YTEN) last posted its quarterly earnings data on Thursday, August 9th. The specialty chemicals company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.03. The business had revenue of $0.29 million during the quarter. Yield10 Bioscience had a negative return on equity of 101.61% and a negative net margin of 1,377.53%. As a group, analysts expect that Yield10 Bioscience will post -0.93 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Yield10 Bioscience stock. Renaissance Technologies LLC grew its stake in Yield10 Bioscience Inc (NASDAQ:YTEN) by 13.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 383,376 shares of the specialty chemicals company’s stock after purchasing an additional 44,300 shares during the period. Renaissance Technologies LLC owned approximately 3.84% of Yield10 Bioscience worth $541,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.63% of the company’s stock.

About Yield10 Bioscience

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.

Further Reading: Ex-Dividend

Get a free copy of the Zacks research report on Yield10 Bioscience (YTEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply